Exploring the time-dependent regulatory potential of microRNAs in breast cancer cells treated with proteasome inhibitors.

Katerina Katsaraki Christos K KontosGerasimos Ardavanis-LoukerisAlexandros A TzovarasDiamantis C Sideris Andreas Scorilas

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)

The diversity of pathways predicted to be affected by the diversity in miRNA expression after treatment with PIs paves the way for the recognition of new regulatory axes in BrCa.

Keyphrases

breast cancer cells
transcription factor
poor prognosis
binding protein
human health
risk assessment
newly diagnosed
breast cancer risk